Clovis Oncology, Inc.
(NASDAQ : CLVS)

( )
CLVS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.12%282.621.4%$842.70m
AMGNAmgen, Inc.
-0.09%220.671.3%$515.31m
CELGCelgene Corp.
-0.64%109.321.3%$463.79m
GILDGilead Sciences, Inc.
-1.20%64.291.0%$395.55m
VRTXVertex Pharmaceuticals, Inc.
0.10%210.001.9%$314.19m
ILMNIllumina, Inc.
0.22%306.673.5%$312.01m
REGNRegeneron Pharmaceuticals, Inc.
-1.36%340.192.6%$264.05m
EXASEXACT Sciences Corp.
0.13%82.1624.0%$210.06m
ALXNAlexion Pharmaceuticals, Inc.
-0.37%107.972.0%$179.14m
SGENSeattle Genetics, Inc.
0.85%115.736.1%$138.13m
BMRNBioMarin Pharmaceutical, Inc.
0.17%75.174.3%$123.85m
SRPTSarepta Therapeutics, Inc.
0.45%97.9014.6%$115.90m
AAgilent Technologies, Inc.
-0.38%77.961.6%$100.97m
NBIXNeurocrine Biosciences, Inc.
1.41%114.645.0%$91.68m
BGNEBeiGene Ltd.
-1.13%196.012.1%$87.64m

Company Profile

Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.